VEGF Trap-Eye shows positive results in a phase 2 study in patients with diabetic macular oedema

VEGF Trap-Eye, the fully human, soluble VEGF receptor fusion protein that binds all forms of VEGF-A along with the related Placental Growth Factor (PIGF), has shown positive results in a Phase 2 study in patients with diabetic macular oedema (DME.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.